CHRS, US19249H1032

Coherus Oncology stock sits at EUR 0.93 with a price-to-earnings ratio of -1.02

Published on 10/15/2026 at 19:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coherus Oncology has a 52-week range of USD 0.97 to USD 2.62 on October 15, 2026. Coherus Oncology stock costs EUR 0.93 on October 15, 2026.

Valuation and trading frame

Coherus Oncology had a price-to-earnings ratio of -1.02 on October 15, 2026.
The stock's 52-week range was USD 0.97 to USD 2.62 on October 15, 2026.
Coherus Oncology stock cost EUR 0.93 at Lang & Schwarz on October 15, 2026 at 7:45 p.m. CEST.
Coherus Oncology had a USD 161.5 million market capitalization on October 15, 2026.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology's price-to-earnings ratio stood at -1.02 on October 15, 2026, while its euro quotation was EUR 0.93 at Lang & Schwarz at 7:45 p.m. CEST. The figure places valuation and trading range at the center of the market report rather than a new corporate announcement.

Range leaves room for volatility

The Nasdaq quote was USD 1.04 on October 15, 2026 at 1:52 p.m. ET, with an intraday range of USD 1.04 to USD 1.09. The 52-week range extended from USD 0.97 to USD 2.62, showing that the latest home-market quote stood above the yearly low and well below the yearly high.

Trading volume reached 576,771 shares against an average of 1,210,057 shares on October 15, 2026. That session volume was lower than the average by 633,286 shares, a concrete sign of lighter activity in the home market.

Valuation and company profile

Coherus Oncology had a market capitalization of USD 161.5 million on October 15, 2026. The company describes itself as a commercial-stage oncology business with the approved LOQTORZI treatment and clinical programs including tagmokitug and casdozokitug, according to Coherus Oncology.

For comparison, CorMedix traded at USD 7.57, up 2.37 percent, with a P/E ratio of 3.55 and a USD 589.6 million market capitalization on October 15, 2026. Iovance Biotherapeutics traded at USD 14.34, up 0.91 percent, with a P/E ratio of -19.68 and a USD 6.5 billion market capitalization on the same date.

Trading snapshot

Coherus Oncology is listed on Nasdaq under CHRS. The company operates in healthcare biotechnology and had 144 full-time employees in the available company profile. Its commercial focus combines oncology products with a pipeline aimed at several solid-tumor indications.

Coherus Oncology stock was trading at EUR 0.93 at Lang & Schwarz on October 15, 2026 at 7:45 p.m. CEST. The Nasdaq quote stood at USD 1.04 on October 15, 2026 at 1:52 p.m. ET, while the euro quotation remained the relevant price for investors in Germany.

The further course of trading is shown by the continuously updated real-time quote of Coherus Oncology stock.